Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

517 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Anti-TNF therapy for other inflammatory conditions.
Tutuncu Z, Morgan GJ Jr, Kavanaugh A. Tutuncu Z, et al. Among authors: kavanaugh a. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S146-51. Clin Exp Rheumatol. 2002. PMID: 12463467 Review.
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH. Furst DE, et al. Among authors: kavanaugh af. Ann Rheum Dis. 2003 Nov;62 Suppl 2(Suppl 2):ii2-9. doi: 10.1136/ard.62.suppl_2.ii2. Ann Rheum Dis. 2003. PMID: 14532138 Free PMC article. Review. No abstract available.
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP, Birbara C, Halter DG, Antoni C; IMPACT 2 Study Group. Kavanaugh A, et al. Ann Rheum Dis. 2007 Apr;66(4):498-505. doi: 10.1136/ard.2006.058339. Epub 2006 Nov 17. Ann Rheum Dis. 2007. PMID: 17114188 Free PMC article. Clinical Trial.
517 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page